Komori
Share Issuance and Disposal4884Kringle Pharma,Inc.Pharmaceuticals

Notice Regarding the Finalization of the Terms of Stock Options (Share Acquisition Rights)

The issue terms, including the exercise price, have been finalized for the 18th Series of Share Acquisition Rights approved on 10 June 2026. Share acquisition rights covering a total of 38,000 shares will be allotted to 7 employees.

Worth reading
36Immaterial
Scored from 3 of 5 sections
Direction
Neutral
Direction inferred from the company’s description.
Scale
38000
Shares
Wording
Definitive
How definitive the wording is.

Details of issuance or disposal

Issue of stock options (share acquisition rights) for employees

Who receives how much

38,000 shares of the Company's common stock (380 share acquisition rights, each covering 100 shares)

7 employees of the Company: 380 share acquisition rights

The lower thin line represents the existing number of shares to which these shares will be added.

Terms of the stock acquisition rights
Exercise price
¥43,100 per share acquisition right (¥431 per share). No adjustment provisions are stated.
Number of Stock Acquisition Rights
Total issued: 380 share acquisition rights. Unexercised balance: Not disclosed.
Categories and Number of Persons Covered
7 employees of the Company, 380 share acquisition rights (covering 38,000 shares)
Basis for determining the amount to be paid
The average closing price of the Company's common stock in regular trading on the Tokyo Stock Exchange on each day in the month preceding the month in which the allotment date falls, excluding days on which no trading took place, was ¥431. If this is below the closing price of ¥318 on the allotment date, the closing price on the allotment date will apply. No discount or premium rate is stated.
Details of issuance or disposal
ItemDetails
Type of issuance or disposalIssue of stock options (share acquisition rights) for employees
Number of shares to be issued or disposed of38,000 shares of the Company's common stock (380 share acquisition rights, each covering 100 shares)
Intended allottee7 employees of the Company: 380 share acquisition rights
Basis for determining the amount to be paidThe average closing price of the Company's common stock in regular trading on the Tokyo Stock Exchange on each day in the month preceding the month in which the allotment date falls, excluding days on which no trading took place, was ¥431. If this is below the closing price of ¥318 on the allotment date, the closing price on the allotment date will apply. No discount or premium rate is stated.
Exercise price¥43,100 per share acquisition right (¥431 per share). No adjustment provisions are stated.
Number of Stock Acquisition RightsTotal issued: 380 share acquisition rights. Unexercised balance: Not disclosed.
Categories and Number of Persons Covered7 employees of the Company, 380 share acquisition rights (covering 38,000 shares)
Items this document does not state (21)
Issue price and disposal priceTotal issue valueAmount of funds to be raisedEstimated issuance expensesSpecific use of fundsPayment dateIntended allottee's holding policyDilution RateTotal number of issued sharesExercise periodTransfer restriction periodConditions for lifting transfer restrictionsReason for acquisition without considerationTotal Stock-Based CompensationUnderwriter / lead underwriterOverallotmentStock Split RatioProcedures under the Corporate Code of ConductMost recent equity financingMajor shareholders after the offeringImpact on Business Performance

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

The issue terms have been finalized. The document does not state the reason for the allotment to employees or the purpose of the issue.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice Regarding the Finalization of the Terms of Stock Options (Share Acquisition Rights) | Kringle Pharma,Inc. (4884) timely disclosure | Komori